Effect of RA-233 on erythrocytes from patients with eczema.
Erythrocytes (RBCs) from patients with eczema are less flexible than erythrocytes obtained from normal healthy individuals. The addition of RA-233 (a membrane-active agent which is a phosphodiestrase inhibitor) improved the deformability of these rigid RBCs, and this improvement was found to be statistically significant at p less than 0.0001. The increase in deformability that was observed after the addition of the drug is assumed to be related to the increases in intracellular Ca2+,K+ and blood ATP levels which are brought about by the action of this drug.[1]References
- Effect of RA-233 on erythrocytes from patients with eczema. Meky, N. Journal of medicine. (1988) [Pubmed]
 
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg









